On the basis of these landmark results of enfortumab vedotin monotherapy for urothelial cancer, phase II clinical trials for the treatment of patients with breast cancer, esophageal cancer, gastric cancer, HNC and non-small cell lung cancer (NSCLC) (EV-202 study, NCT04225117), adenoid cystic carcinoma (NCT06891560), colorectal cancer or hepatocellular carcinoma (NCT06553885), pancreatic cancer (NCT05915351) and prostate cancer (NCT04754191) are ongoing to expand the indication of enfortumab vedotin monotherapy to other types of NECTIN4-positive cancers (Table 1). Here, NECTIN4 is linked to familial pancreatic carcinoma.